The invention relates to bis(aniline) compounds containing multiple arylethynyl, alkylethynyl, ethynyl groups or their combinations, processes of making such compounds and materials comprising such compounds. Such, bis(aniline) compounds preferably comprise multiple phenylethynyl (PE) groups, i.e. 2-4 PE moieties. Such compounds are useful monomers for the preparation of polyimides, polyamides and poly(amide-imides) whose post-fabrication crosslinking chemistry (i.e. reaction temperature) can be controlled by the number of PE per repeat unit as well as finding utility in thermosetting matrix resins, 3D printable resins, and as high-carbon-content precursors to carbon-carbon composites.

The invention relates to bis(aniline) compounds containing multiple arylethynyl, alkylethynyl, ethynyl groups or their combinations, processes of making such compounds and materials comprising such compounds. Such, bis(aniline) compounds preferably comprise multiple phenylethynyl (PE) groups, i.e. 2-4 PE moieties. Such compounds are useful monomers for the preparation of polyimides, polyamides and poly(amide-imides) whose post-fabrication crosslinking chemistry (i.e. reaction temperature) can be controlled by the number of PE per repeat unit as well as finding utility in thermosetting matrix resins, 3D printable resins, and as high-carbon-content precursors to carbon-carbon composites.

The present disclosure relates to compounds of Formula (I):

##STR00001##

and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

The present disclosure relates to compounds of Formula (I):

##STR00001##

and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

A fabricating method for a 1,4-diamine cyclic compound derivative includes: performing a first thermal process to form a first compound, in which the first compound has a structure represented by formula (i): ##STR00001##
in which R represents a C1 to C12 hydrocarbon group; performing a second thermal process, which includes performing a reduction reaction on the first compound to form a second compound, in which the second compound has a structure represented by formula (ii), ##STR00002##
and performing a third thermal process, which includes performing a reduction reaction on the second compound to form the 1,4-diamine cyclic compound derivative, in which the 1,4-diamine cyclic compound derivative has a structure represented by formula (I) or formula (II): ##STR00003##
in which R represents a C1 to C12 hydrocarbon group, ##STR00004##
in which R represents a C1 to C12 hydrocarbon group.

A fabricating method for a 1,4-diamine cyclic compound derivative includes: performing a first thermal process to form a first compound, in which the first compound has a structure represented by formula (i): ##STR00001##
in which R represents a C1 to C12 hydrocarbon group; performing a second thermal process, which includes performing a reduction reaction on the first compound to form a second compound, in which the second compound has a structure represented by formula (ii), ##STR00002##
and performing a third thermal process, which includes performing a reduction reaction on the second compound to form the 1,4-diamine cyclic compound derivative, in which the 1,4-diamine cyclic compound derivative has a structure represented by formula (I) or formula (II): ##STR00003##
in which R represents a C1 to C12 hydrocarbon group, ##STR00004##
in which R represents a C1 to C12 hydrocarbon group.

A catalytic membrane composite that includes porous supported catalyst particles durably enmeshed in a porous fibrillated polymer membrane is provided. The porous fibrillated polymer membrane may be manipulated to take the form of a tube, disc, or diced tape and used in multiphase reaction systems. The supported catalyst particles are composed of at least one finely divided metal catalyst dispersed on a porous support substrate. High catalytic activity is gained by the effective fine dispersion of the finely divided metal catalyst such that the metal catalyst covers the support substrate and/or is interspersed in the pores of the support substrate. In some embodiments, the catalytic membrane composite may be introduced to a stirred tank autoclave reactor system, a continuous flow reactor system, or a Parr Shaker reaction system and used to effect the catalytic reaction.

A catalytic membrane composite that includes porous supported catalyst particles durably enmeshed in a porous fibrillated polymer membrane is provided. The porous fibrillated polymer membrane may be manipulated to take the form of a tube, disc, or diced tape and used in multiphase reaction systems. The supported catalyst particles are composed of at least one finely divided metal catalyst dispersed on a porous support substrate. High catalytic activity is gained by the effective fine dispersion of the finely divided metal catalyst such that the metal catalyst covers the support substrate and/or is interspersed in the pores of the support substrate. In some embodiments, the catalytic membrane composite may be introduced to a stirred tank autoclave reactor system, a continuous flow reactor system, or a Parr Shaker reaction system and used to effect the catalytic reaction.

The present invention relates to an activated carbon having an electric conductivity of 3.5 S/cm or more obtained by powder resistance measurement under a load of 12 kN and an oxygen content of 3.0% by mass or more, and a metal-carrying activated carbon using the same, and the like.

A method for producing a compound represented by formula (C) wherein R.sup.1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R.sup.1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).

##STR00001##